NCT04181827 2026-03-16
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT04162210 2026-02-11
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT06956170 2025-06-11
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04484623 2025-03-18
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
NCT01712789 2022-01-10
STRATUS
Celgene
Phase 3 Completed
NCT02576977 2021-10-08
KEYNOTE 183
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03440411 2021-03-10
PO-3887
Fondazione EMN Italy Onlus
Phase 3 Terminated
NCT01324947 2019-11-19
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Celgene
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed